Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
36 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Halozyme Therapeutics, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Halozyme Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Halozyme Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Halozyme Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Halozyme Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Halozyme Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Halozyme Therapeutics, Inc.'s pipeline products Reason to Buy - Evaluate Halozyme Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Halozyme Therapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Halozyme Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Halozyme Therapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Halozyme Therapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Halozyme Therapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Halozyme Therapeutics, Inc. Snapshot 5 Halozyme Therapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 Halozyme Therapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Halozyme Therapeutics, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Halozyme Therapeutics, Inc. - Pipeline Products Glance 14 Halozyme Therapeutics, Inc. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Halozyme Therapeutics, Inc. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Halozyme Therapeutics, Inc. - Drug Profiles 17 Analog Insulin-PH20 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 HTI-501 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 PEGPH-20 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Halozyme Therapeutics, Inc. - Pipeline Analysis 21 Halozyme Therapeutics, Inc. - Pipeline Products by Target 21 Halozyme Therapeutics, Inc. - Pipeline Products by Route of Administration 22 Halozyme Therapeutics, Inc. - Pipeline Products by Molecule Type 23 Halozyme Therapeutics, Inc. - Pipeline Products by Mechanism of Action 24 Halozyme Therapeutics, Inc. - Recent Pipeline Updates 25 Halozyme Therapeutics, Inc. - Dormant Projects 30 Halozyme Therapeutics, Inc. - Company Statement 31 Halozyme Therapeutics, Inc. - Locations And Subsidiaries 34 Head Office 34 Other Locations & Subsidiaries 34 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 35 Contact Us 35 Disclaimer 36
List of Tables
Halozyme Therapeutics, Inc., Key Information 5 Halozyme Therapeutics, Inc., Key Facts 5 Halozyme Therapeutics, Inc. - Pipeline by Indication, 2015 7 Halozyme Therapeutics, Inc. - Pipeline by Stage of Development, 2015 8 Halozyme Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 9 Halozyme Therapeutics, Inc. - Partnered Products in Pipeline, 2015 10 Halozyme Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 11 Halozyme Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2015 12 Halozyme Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 13 Halozyme Therapeutics, Inc. - Phase II, 2015 14 Halozyme Therapeutics, Inc. - Phase I, 2015 15 Halozyme Therapeutics, Inc. - Preclinical, 2015 16 Halozyme Therapeutics, Inc. - Pipeline by Target, 2015 21 Halozyme Therapeutics, Inc. - Pipeline by Route of Administration, 2015 22 Halozyme Therapeutics, Inc. - Pipeline by Molecule Type, 2015 23 Halozyme Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015 24 Halozyme Therapeutics, Inc. - Recent Pipeline Updates, 2015 25 Halozyme Therapeutics, Inc. - Dormant Developmental Projects,2015 30 Halozyme Therapeutics, Inc., Subsidiaries 34
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.